At $1,800 for a business-class ticket, the Colorado Convention Center's Bellco Theater is full on Friday night with the who's-who of a burgeoning psychedelics industry that's predicted to be worth $100 billion by 2030. The dress code is "psychedelic business casual" on the final night of Psychedelic Science 2023 — the largest conference of its kind in history with more than 11,000 attending, according to event sponsors the Multidisciplinary Association for Psychedelic Studies (MAPS).
The man of the hour is MAPS President Rick Doblin. His legacy spearheading the campaign for FDA-approved MDMA trials and a lifetime spent bouncing around psychedelic research units have led him to the Denver stage. He steps out to greet a roaring crowd, ready to deliver the week-long conference's closing remarks.
